secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0000875045-25-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance
-------------------------------------------------------------------------

- Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).
- Raised FY2025 Non-GAAP EPS guidance to $15.50-$16.00 (from $14.50-$15.50); revenue now expected ~flat vs 2024.
- LEQEMBI U.S. in-market sales ~$63M (+20% sequential); global ~$160M incl. $35M one-time China shipment.
- SKYCLARYS global rev. ~$130M; U.S. ~$78M (+13% seq.); ZURZUVAE $46M (+68% seq.).
- Pipeline: salanersen advancing to registrational stage in SMA; felzartamab Phase 3 initiated in rare kidney diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/0000875045-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/biib-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000875045-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer